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DNA repair factor BRCA1 depletion occurs in
Alzheimer brains and impairs cognitive function
in mice
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Mariel Finucane3, Joseph Knox1, Kaitlyn Ho1, Nino Devidze1,w, Eliezer Masliah4,5 & Lennart Mucke1,2
Maintaining DNA integrity is vital for all cells and organisms. Defective DNA repair may
contribute to neurological disorders, including Alzheimer’s disease (AD). We found reduced
levels of BRCA1, but not of other DNA repair factors, in the brains of AD patients and human
amyloid precursor protein (hAPP) transgenic mice. Amyloid-b oligomers reduced BRCA1
levels in primary neuronal cultures. In wild-type mice, knocking down neuronal BRCA1 in the
dentate gyrus caused increased DNA double-strand breaks, neuronal shrinkage, synaptic
plasticity impairments, and learning and memory deficits, but not apoptosis. Low levels of
hAPP/Amyloid-b overexpression exacerbated these effects. Physiological neuronal activation
increased BRCA1 levels, whereas stimulating predominantly extrasynaptic N-methyl-D-
aspartate receptors promoted the proteasomal degradation of BRCA1. We conclude that
BRCA1 is regulated by neuronal activity, protects the neuronal genome, and critically supports
neuronal integrity and cognitive functions. Pathological accumulation of Ab depletes neuronal
BRCA1, which may contribute to cognitive deficits in AD.
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E
ffective repair of DNA damage is essential for the survival of
cells and most individual organisms and species. Ineffective
repair can result in cell death, cancer and neurological
disease1,2. Alzheimer’s disease (AD) and other neurodegenerative
disorders are associated with excessive neuronal DNA damage3.
We have shown that physiological increases in brain activity
transiently increase neuronal DNA double-strand breaks (DSBs)
without causing neuronal apoptosis4. In wild-type (WT) mice, the
DSBs were rapidly repaired after neuronal activity returned to
baseline. Human amyloid precursor protein (hAPP) transgenic
mice from line J20, which simulate key aspects of AD5, had
higher levels of neuronal DSBs at baseline and abnormal
persistence of activity-induced neuronal DSBs4. In principle,
these alterations could result from excessive formation or
defective repair of DSBs. Because DNA repair is defective in
several neurodegenerative diseases1,2, we hypothesized that the
abnormal accumulation of DSBs in neurons of hAPP mice is
caused by alterations in their DNA repair machinery.
We show that the levels of a specific DNA repair factor are
decreased in brains of hAPP-J20 mice and of patients with AD.
Knocking down this factor in the dentate gyrus (DG) of mice
increased neuronal DSB levels in this brain region and caused
behavioural deficits without causing neuronal loss.
Results
BRCA1 depletion in hAPP brains and in neurons exposed to
Ab. We compared the levels of key components of the DSB repair
machinery in hAPP-J20 mice and WT controls. In DG, where
neuronal DSBs and other biochemical alterations differ most
between these groups4,6,7, hAPP-J20 mice had a selective, almost
70% reduction in breast cancer factor 1 (BRCA1), whereas
MRE11, NBS1 and RAD51 levels were unaffected (Fig. 1a,b). In
parietal cortex, BRCA1 levels were decreased by 45% in hAPP-J20
mice (Supplementary Fig. 1a,b). hAPP-J20 mice had normal
levels of BRCA1 mRNA in the DG and parietal cortex (Fig. 1c
and Supplementary Fig. 1c), suggesting post-transcriptional
depletion of BRCA1 protein.
Ab1–42 oligomers, the most likely mediators of Ab-dependent
neuronal dysfunction8, reduced BRCA1 levels in primary
neuronal cultures by 50% and increased levels of the DSB
marker gH2A.X by 70% (Fig. 1d). Thus, high levels of soluble Ab
assemblies, which also occur in brains of hAPP mice and AD
patients8, can reduce neuronal BRCA1 levels.
BRCA1 is a 208-kDa protein with multiple isoforms and, in
mutant form, has been studied primarily as a genetic risk factor
for ovarian and breast cancers9. BRCA1 binds directly to DSBs
bearing the histone variant gH2A.X, recruiting other repair
factors and chromatin modifiers to suppress nuclease activity
around DSBs and promote repair9,10. In proliferating cells,
BRCA1 promotes DSB repair by homologous recombination9,11,
an unlikely event in differentiated neurons2. In developing brain,
BRCA1 is required for neuronal progenitors to survive12. Its roles
in mature brain are largely unknown. Striatal BRCA1 levels are
altered in a Huntington’s disease model10.
BRCA1 levels are reduced in the brains of AD patients. To
determine whether BRCA1 is altered in humans with AD, we
immunostained post-mortem brain sections from people who
had no cognitive deficits and a Braak score of 0 (controls) and
from patients with mild cognitive impairment (MCI) or AD with
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Figure 1 | BRCA1 reduction in brain tissues from hAPP-J20 mice and in primary neurons exposed to Ab oligomers. (a,b) Levels of DNA repair factors
BRCA1, Rad51, NBS1 and MRE11, and of histone 3 dimethylated on lysine 9 (Me2H3(K9)) in the DG of WTand hAPP-J20 mice. (a) Representative western
blot. (b) Quantitation of western blot signals. The average DNA-repair factor or histone to a-tubulin ratio in WTmice was arbitrarily defined as 1.0.
n¼ 17–20 mice per genotype for BRCA1 and n¼ 12–14 mice per genotype for the other proteins. Age, 4–8 months. (c) Levels of BRCA1 mRNA in the DG
were assessed by RT–qPCR. The average BRCA1 to GAPDH mRNA ratio in WTmice was arbitrarily defined as 1.0. n¼ 11–13 mice per genotype. Age, 4–6
months. (d) Cultures of primary hippocampal neurons fromWTmice were exposed to Ab oligomers (1mM) (þ ) or vehicle (–) for 5 h. Levels of BRCA1 and
the DSB marker gH2A.X were determined by western blotting. The average DNA-repair factor to a-tubulin ratio in vehicle-treated cultures was defined as
1.0. n¼6–8 wells per condition from three independent experiments. In western blots each lane contained a sample from a different mouse (a) or culture
well (d). *Po0.05, **Po0.01, ***Po0.001 versus WT (b) or vehicle (d) by t-test (with Welch correction in d). Bars represent means±s.e.m.
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an antibody against BRCA1. Hippocampal neurons showed
punctate BRCA1 immunoreactivity in the nucleus and cytoplasm
(Fig. 2a and Supplementary Fig. 2a,b). In neuronal cell bodies, the
number of BRCA1-immunoreactive punctae in MCI and AD
patients was 65% lower in the CA1 and CA3 regions and 75%
lower in the DG than in controls (Fig. 2b). In both MCI and AD
patients, BRCA1 reductions were comparable in neuronal nuclei
and cytoplasm in CA1, but significant only in neuronal nuclei in
the DG (Supplementary Fig. 2b,c), probably because nuclei
occupy most of the cell body in dentate granule cells.
In contrast to the reduced BRCA1 levels we identified in
neurons that still showed grossly normal morphologies, BRCA1
immunoreactivity was increased in several histopathological lesions
typically seen in AD brains, such as amyloid plaques, dystrophic
neurites and granulovacuolar degeneration (Fig. 2c), consistent
with previous reports13,14. Overall, though, BRCA1 levels in the
inferior parietal cortex were 50–70% lower in MCI and AD
patients than in controls (Fig. 2d), suggesting that the predominant
change in these patients is the neuronal depletion of BRCA1.
BRCA1 knockdown increases neuronal DSBs. To assess
pathophysiological consequences of reduced neuronal BRCA1
levels, we used lentiviral vectors expressing enhanced green
fluorescent protein (eGFP) and one of two distinct anti-BRCA1
shRNAs (sh1 or sh2) to knock down BRCA1. In proliferating
ovarian carcinoma cells, expression of sh1 had the same
effects as genetic ablation of BRCA1 (ref. 15). In primary
neuronal cultures, sh1 and sh2 reduced BRCA1 mRNA and
protein levels (Supplementary Fig. 3a–c) and BRCA1 immunor-
eactivity in both the nucleus and the cytoplasm (Supplementary
Fig. 3d,e).
We injected sh1 or sh2 bilaterally into the DG of WT mice
(Fig. 3a). To determine whether mice with moderate neuronal
overexpression of human hAPP/Ab have increased sensitivity to
neuronal BRCA1 knockdown, we also injected hAPP mice
from the lower expresser line J9 (hAPPlow), which have minimal
or no behavioural deficits at baseline16. Mice injected with a
lentiviral vector expressing eGFP and scrambled shRNA (scr)
served as negative controls.
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Figure 2 | Neuronal BRCA1 reduction in AD patients. (a–c) Brain sections containing CA and DG from human cases with CDR/Braak scores of 0/0–I
(control), 0.5/0–III (MCI) or þ 1/IV–VI (AD) were immunostained for BRCA1 (n¼ 8 subjects per group). (a) Representative micrographs showing BRCA1-
immunoreactive neurons in the CA1, CA3 and DG regions of the hippocampus. Scale bar, 10mm. (b) Immunoreactive punctae were counted in 100 cells per
subject and region. The average number of punctae per cell (CA1 and CA3) or per 100 cells (DG) is shown. (c) Representative micrographs of brain
sections from AD patients showing BRCA1 immunoreactivity of an amyloid plaque, a dystrophic neurite (arrowheads), and a neuron with granulovacuolar
degenerative (GVD) alterations (arrow). Scale bars, 10mm. (d) BRCA1 levels in the parietal cortex of humans with Braak scores of 0–1 (control, n¼9), 2–5
(mild to moderate AD, n¼ 5) orZ6 (severe AD, n¼ 8) determined by western blot analysis. The average BRCA1 to a-actin ratio in controls was defined as
1.0. **Po0.01, ***Po0.001 versus control by Dunnett test. Bars represent means±s.e.m.
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Mice were injected at 1–2 months (scr and sh1 comparison)
or 2.5–4 months (scr, sh1 and sh2 comparison) of age and
analysed 1–3 months later. As with similar viral vectors
encoding other shRNAs that we used in previous studies6,
50–80% of granule cells were GFP positive within 1 month after
the injection regardless of the shRNA or the group of mice
injected. The majority of GFP-positive cells were neurons,
as judged from the shapes of their cell bodies and processes,
the size of their nuclei and the co-localization of GFP with
microtubule-associated protein 2 (MAP2) (Supplementary
Figs 3d and 4a), a specific marker of neuronal cell bodies and
dendrites.
Two to three months after viral injections, BRCA1 levels in the
DG were 40–50% lower in WT mice expressing sh1 or sh2 than in
WT mice expressing scr (Fig. 3b,c and Supplementary Figs 4b–e).
The BRCA1 signal ratio of transduced to nontransduced neurons
was 40% lower in sh1-injected WT and hAPPlow mice than in scr-
injected WT and hAPPlow mice (Supplementary Fig. 4c–e).
BRCA1 levels in the DG were lower in uninjected hAPP-J20 mice
than in uninjected WT mice (Fig. 1b), but not significantly
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Figure 3 | Knockdown of BRCA1 increases neuronal DSBs in the DG of mice. WTand hAPPlow mice received stereotaxic injections of lentivirus encoding
eGFP plus anti-BRCA1 shRNA (LV-shBRCA1-GFP (sh1)) or scrambled shRNA (LV-Scr-GFP (scr)) into the DG at 1–2 months of age and were analysed 3
months later. (a) Sh1 expression (green) in a DAPI-labelled (blue) coronal brain section from aWTmouse was visualized by fluorescence microscopy. Scale
bar, 1mm. (b) Western blots illustrating particularly effective knockdowns of BRCA1 in the DG. A unit of 50 (top) or 20mg (bottom) of total protein was
loaded per well. (c) BRCA1 levels in the DG were normalized as in Fig. 1b. n¼ 14–17 mice per genotype and treatment from three cohorts. (d) DSB levels in
cell nuclei isolated from DG homogenates were assessed by comet assay at neutral pH. The percent of nuclei with comet tails, reflecting DNA
fragmentation, is shown (n¼ 3–5 mice per genotype and treatment). (e) Confocal micrograph of granule cells in the DG of a WT-sh1 mouse showing three
typical 53BP1-immunoreactive foci (red) in the nucleus of one of the neurons (white arrowhead), GFP immunostaining of transduced cells (green)
and DAPI labelling of nuclei (blue). Scale bar, 10mm. (f–i) Dentate granule cells with 53BP1-positive (f,i) or gH2A.X-positive (g,h) foci were counted in three
(f) or two (g–i) sections per mouse. (f) Number of granule cells per section with 53BP1-positive foci (n¼ 7–10 mice per genotype and treatment).
(g) Number of granule cells per section with gH2A.X-positive foci (n¼4–6 mice per genotype and treatment). (h) Percentage of gH2A.X-positive cells
per section with Z3 gH2A.X foci (n¼4–6 mice per genotype and treatment). (i) Number of granule cells per section with 53BP1-positive foci in scr- or
sh1-injected WTmice analysed after they remained in their home cage, explored a novel environment for 2 h (Novel E), or explored the novel environment
for 2 h and were returned to their home cage for 24 h (Recovery). n¼4–13 mice per condition. *Po 0.05, **Po0.01, ***Po0.001 versus leftmost bar or as
indicated by brackets (Bonferroni test). NS, not significant. Bars represent means±s.e.m.
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different in scr-injected hAPPlow and WT mice (Fig. 3c and
Supplementary Fig. 4b), although hAPPlow mice showed a trend
towards lower levels. BRCA1 levels were slightly, but insignif-
icantly, lower in sh1-expressing hAPPlow mice than in sh1-
expressing WT mice (Fig. 3c). Thus, expression of either of two
shRNAs targeting BRCA1 mRNA effectively lowered BRCA1
levels, and Ab-dependent reductions in BRCA1 may require a
certain threshold level of Ab expression.
To determine whether neuronal knockdown of BRCA1 affects
DNA integrity, we measured nuclear DNA fragmentation in a
comet assay at neutral pH17. We isolated cell nuclei from DG and
determined the proportion of nuclei with comet tails and the
length of the tails (Fig. 3d and Supplementary Fig. 5a,b), which
reflect the prevalence and extent of DSBs, respectively17. BRCA1
knockdown increased the proportion of nuclei with comet tails in
hAPPlow mice and was associated with a trend in this direction in
WT mice (Fig. 3d). The severity of DNA damage, reflected in the
length of comet tails, did not differ significantly among the
groups (Supplementary Fig. 5b).
We also immunostained brain sections with antibodies against
53BP1 and gH2A.X, which form nuclear foci around DSBs
(Fig. 3e)4,11. sh1-injected mice had 1.6-fold (WT) to 2-fold
(hAPPlow) more cells with 53BP1-positive foci per DG section
than scr-injected controls (Fig. 3f). sh1-injected mice had 2-fold
(WT) to 2.6-fold (hAPPlow) more cells with gH2A.X-positive foci
per DG section than scr-injected controls (Fig. 3g). Baseline
numbers of cells with gH2A.X-positive foci in scr-injected mice
were slightly higher than those we previously observed in
uninjected WT mice4, possibly due to the viral infection per se
or the co-expression of eGFP. hAPPlow expression increased both
the number of cells with foci and the percentage of cells withZ3
gH2A.X-positive foci in sh1-injected mice (Fig. 3g,h), suggesting
that even low levels of hAPP/Ab overexpression can exacerbate
the severity of DNA damage when BRCA1 levels are reduced.
Similar results were obtained with sh2 (Supplementary Fig. 5c–e).
Taken together, these findings suggest that BRCA1 critically
contributes to DSB repair in central neurons.
The increase in DSBs caused by sh1 expression in WT and
hAPPlow mice was smaller than the threefold increase in DSBs
detected by comet assay and 53BP1 immunostaining in uninjected
hAPP-J20 mice, as compared with uninjected WT controls4. This
difference probably reflects a BRCA1 dose effect, as levels of
BRCA1 in the DG were lower in uninjected hAPP-J20 mice
(Fig. 1a) than in sh1-injected WT and hAPPlow mice (Fig. 3c).
Physiological increases in neuronal activity transiently increase
neuronal DSBs in WT mice4. To test the role of BRCA1 in the
repair of DSBs generated in response to physiological activation,
we let sh1- or scr-injected WT mice explore a novel environment
for 2 h. In all mice the number of dentate granule cells with
53BP1 foci increased immediately after the exploration (Fig. 3i).
When replicate groups of mice were analysed 24 h after the
exploration, the number of neurons with 53BP1-positive foci
had returned to baseline levels in scr-injected mice but not in
sh1-injected mice (Fig. 3i), suggesting that BRCA1 contributes to
the repair of activity-induced DSBs.
Knockdown of BRCA1 does not cause neuronal apoptosis.
Since physiological increases in neuronal activity transiently
increase neuronal DSBs in WT mice, it is unlikely that moderate
increases in DSBs cause neuronal loss. Furthermore, hAPP-J20
mice have decreased hippocampal BRCA1 levels (Fig. 1a,b) and
an increased proportion of neurons with DSBs4, but no overt
neuronal loss7. Consistent with these observations, we found no
increases in TUNEL-stained dentate granule cells in sh1-injected
WT and hAPPlow mice (Supplementary Fig. 6).
Since neurogenesis in the subgranular zone of the DG
continues into adulthood and newly born granule cells appear
to be more sensitive to DNA damage than mature granule cells12,
we immunostained brain sections for doublecortin, a specific
marker of newly born neurons18. sh1 tended to decrease the
number of doublecortin-positive cells in WT and hAPPlow mice
but not significantly (Supplementary Fig. 7). Immunostaining of
brain sections from the same mice revealed significantly more
53BP1-positive neurons and less BRCA1 immunoreactivity in
sh1-injected mice (Fig. 3f and Supplementary Fig. 4b,c),
confirming the effectiveness of the BRCA1 reduction.
BRCA1 reduction causes learning and memory deficits in mice.
To assess whether reductions in BRCA1 and increases in neu-
ronal DSBs affect cognitive functions, we used the Morris water
maze (MWM) and a place recognition paradigm. In the hidden-
platform component of the MWM task, which requires both
procedural and spatial learning, all groups of mice learned to use
extramaze cues to find the platform (Fig. 4a,b). sh1-mediated
knockdown of BRCA1 impaired task acquisition in WT and
hAPPlow mice (Fig. 4a,b; Po0.0001 versus scr-injected controls
by Bayesian modelling). While the learning curves of scr-injected
WT and hAPPlow mice were not significantly different (P¼ 0.74),
sh1-injected hAPPlow mice were more impaired than sh1-injected
WT mice (Po0.05), suggesting a greater susceptibility of hAPPlow
mice to BRCA1 knockdown. sh1-injected hAPPlow mice per-
formed as poorly as uninjected hAPP-J20 mice6,7, which have
higher levels of Ab in the brain19 and reduced BRCA1 levels in
the DG at baseline (Fig. 1a).
A more detailed analysis of trial-by-trial data by Bayesian
modelling revealed additional differences among the groups
(Fig. 4b). On most training days, all groups improved their
performance across the four daily trials (Po0.0001). However,
from one day of training to the next, hAPPlow mice had greater
setbacks in escape latency than WT mice. While in scr-injected
hAPPlow mice there was only a trend in this direction
(Supplementary Fig. 8a), in sh1-injected hAPPlow mice the
difference in inter-day setbacks became significant (P¼ 0.02)
during the last 3 days of training (Supplementary Fig. 8b),
suggesting that BRCA1 reduction elicits or exacerbates an hAPP/
Ab-dependent deficit in memory consolidation.
In a probe trial (platform removed) 24 h after the end of
training, sh1-injected WT and hAPPlow mice showed less
preference for the original platform location (Fig. 4c) and the
target quadrant (Supplementary Fig. 8c) than scr-injected mice.
sh1-injected WT, but not hAPPlow, mice showed a trend towards
crossing the platform location more often than corresponding
locations in nontarget quadrants (Fig. 4c). Thus, hAPPlow mice
may be more susceptible to BRCA1 knockdown.
The four groups did not differ in swim speeds (Supplementary
Fig. 8d) or escape latencies to a visibly cued platform
(Supplementary Fig. 8e). Nor did they differ in exploration and
anxiety-like behaviours in an elevated plus maze, although sh1-
and scr-injected hAPPlow mice tended to spend more time in the
open arms (Supplementary Fig. 8f), an abnormality seen more
prominently in hAPP-J20 mice and other high-expresser hAPP
lines16,20.
Knocking down BRCA1 in both DG with a different shRNA
(sh2) also caused spatial learning and memory deficits in the
MWM (Fig. 4d and Supplementary Fig. 9a–c).
In a novel place recognition task6 that engages the DG21, mice
were allowed to explore two objects within an arena. Three hours
later, they were reintroduced into the arena after one of the
objects had been moved. Scr-injected WT and hAPPlow mice, but
not sh1- or sh2-injected mice, spent more time exploring the
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moved object (Fig. 4e,f)—additional evidence that neuronal
BRCA1 reduction in the DG interferes with spatial learning and
memory. DG injection with sh1 or sh2 did not significantly alter
behaviour in an open field containing no objects (Supplementary
Fig. 9d,e).
Neuronal BRCA1 levels are regulated by neuronal activity. To
assess whether neuronal BRCA1 expression is regulated by
neuronal activity, we allowed some WT mice to explore a novel
environment for 2 h and kept others in their home cages.
Exploratory activity increased BRCA1 levels in the DG (Fig. 5a,b)
and N-methyl-D-aspartate (NMDA) treatment increased BRCA1
levels in primary neuronal cultures (Fig. 5c), most likely in
response to the neuronal DSB formation caused by this stimu-
lation4. Exploration of a novel environment also increased
BRCA1 levels in hAPP-J20 mice (Fig. 5a,b), suggesting intact
upregulation of BRCA1 in response to DSBs or neuronal activity.
However, like baseline levels, BRCA1 levels after exploration were
lower in hAPP-J20 than WT mice, which may explain, at least in
part, the abnormal persistence of exploration-induced neuronal
DSBs in hAPP-J20 mice4.
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Figure 4 | Knockdown of BRCA1 in DG impairs spatial learning and memory in mice.Mice (n¼ 18–28 per genotype and treatment) received injections of
scr or sh1 into the DG at 1–2 months of age (a–c,e) as in Fig. 3. An independent cohort of mice (n¼6–11 per genotype and treatment) was treated similarly
to compare the effects of scr, sh1 and sh2 (d,f). Mice were tested in the MWM (a–d) and a novel place recognition test (e,f) either 1 (a–d) or 2 (e,f)
months after injection. (a) Learning curves show mean daily escape latencies calculated from four trials per day. (b) Trial-by-trial data were analysed with a
Bayesian model yielding posterior mean learning curve estimates (lines) and 95% credible intervals (CI, shaded regions). Broken up in segments of four
trials per day, learning curve estimates show changes in performance across trials per day and across days. There was no significant interaction between
the effects of genotype and treatment on learning rate (P¼0.16), although sh1 injection tended to affect WTmice less than hAPPlow mice (WT: sh1 0.9 s
per trial (CI 0.6–1.2) versus scr 1.6 s per trial (CI 1.3–1.9; P¼0.004); hAPPlow: sh1 0.4 s per trial (95% CI 0.1–0.7) versus scr 1.6 s per trial (CI 1.2–1.9),
Po0.0001). (c) Number of times mice crossed the original platform (Target) location versus corresponding locations in other quadrants (Other) during a
60-s probe trial 24 h after hidden-platform training. *Po0.05, ***Po0.001 versus same genotype injected with scr (Bonferroni test) or as indicated by
brackets (paired t-test). (d) Learning curves show mean daily escape latencies calculated from four trials per day. (e,f) Spatial memory assessed in a novel
place recognition task 3 h after training. Bars represent the time mice spent exploring the object that was moved (New) or not (Old), expressed as
percentage of the total time spent exploring either object. *Po0.05, ***Po0.001 versus chance (dashed line) (one-sample t-test). Values are
means±s.e.m. (a,c,d–f) or means±95% CI (b). NS, not significant.
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Since our previous findings suggested that abnormal activation
of extrasynaptic NMDARs is critically involved in the Ab-
induced accumulation of DSBs4, we examined whether activation
of these receptors affects BRCA1 levels. Five hours after
stimulation of extrasynaptic NMDARs, levels of BRCA1 and
pERK1/2 decreased by 50% (Fig. 5d–f). In contrast, BRCA1
mRNA levels were increased 1 h after treatment of cultures with
NMDA and 5 h after activation of extrasynaptic NMDARs
(Fig. 5g), suggesting a post-transcriptional mechanism of the
BRCA1 protein depletion. Because degradation by the ubiquitin
proteasome pathway regulates BRCA1 levels in dividing cells22
and is also involved in the reduction of pERK1/2 after stimulation
of extrasynaptic NMDARs23, we pretreated neurons with the
proteasome inhibitor MG132. Inhibition of this pathway
prevented reductions in both BRCA1 and pERK1/2 (Fig. 5d–f),
suggesting that activation of extrasynaptic NMDARs causes
proteasomal degradation of BRCA1.
BRCA1 depletion alters neuronal structure and function.
Learning and memory deficits can arise from a variety of
pathological changes in neuronal morphology and function, and
several of these alterations occur in diseases associated with
changes in DNA integrity and genomic stability2,24,25. To
examine the effect of BRCA1 reduction on neuronal structure
and function, we investigated the morphological and
electrophysiological characteristics of scr- and sh1-expressing
dentate granule cells. We prepared acute hippocampal slices
from scr- or sh1-injected WT mice and targeted GFP-positive
cells in the DG for whole-cell patch-clamp recordings while
simultaneously filling the recorded cells with biocytin.
Morphometric analysis of filled neurons revealed that sh1-
expressing neurons had smaller cell bodies (Fig. 6a,b) and
dendritic arbours (Fig. 6c,d) than scr-expressing neurons.
Consistent with the shrinkage in cell size and dendritic
arbour, BRCA1 reduction also increased the resting membrane
resistance (Fig. 6e) and intrinsic excitability (Fig. 6f–h and
Supplementary Fig. 10a,b) of dentate granule cells. Compared
with scr-expressing neurons, sh1-expressing neurons also had a
higher instantaneous frequency of action potentials as a function
of stimulation current (Fig. 6g,h), lower (more negative)
spike threshold (Supplementary Fig. 10a) and reduced spike after
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Figure 5 | Neuronal activity regulates BRCA1 levels. (a,b) BRCA1 levels in the DG were determined by western blot analysis in WT and hAPP-J20 mice
that remained in their home cage or explored a novel environment for 2 h (Novel E). (a) Western blot showing typical activity-induced increases in BRCA1
levels and particularly marked reductions in baseline BRCA1 levels in hAPP mice. (b) For quantitation, the average BRCA1 to a-tubulin ratio in WTmice
(home cage) was defined as 1.0. n¼ 8–19 mice per group from two independent experiments. (c) Cultures of primary hippocampal neurons from WTmice
were stimulated with NMDA (þ ) or treated with vehicle (–). One hour later, BRCA1 levels were determined by western blotting. The average ratio of
BRCA1 to a-tubulin in vehicle-treated cultures was defined as 1.0. n¼4–6 wells per condition from two independent experiments. (d–f) Cultures of primary
hippocampal neurons from WTmice were incubated with the proteasome inhibitor MG132 (þ ) or with vehicle (–) starting 1 h before stimulation of
extrasynaptic NMDARs (ExtraS). Four hours later, BRCA1 levels were determined by western blotting. (d) Representative western blots. (e) Quantitation of
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neurons from WTmice were treated as indicated, and BRCA1 mRNA levels were quantitated by RT–qPCR. The average BRCA1 to GAPDH mRNA ratio in
vehicle-treated cultures was defined as 1.0. n¼6 wells per condition from two independent experiments. *Po0.05, **Po0.01, ***Po0.001 versus leftmost
bar or as indicated by brackets by Bonferroni test (b,e,f), unpaired t-test (c) or Dunnett’s test (g). Bars represent means±s.e.m. NS, not significant.
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hyperpolarization (Supplementary Fig. 10b). Interestingly,
as shown in the representative action potential traces
(Fig. 6f), reduction of BRCA1 levels also impaired the cells’
ability to sustain prolonged action potential firing, thereby
leading to a decrease in the average firing frequency over
time (Fig. 6i,j).
To examine circuit modifications that may arise from the
observed cellular alterations and may underlie cognitive
impairments in sh1-injected mice, we assessed synaptic plasticity
between granule cells and CA3 neurons by stimulating mossy
fibres and recording field excitatory postsynaptic potentials
(fEPSPs) in CA3 stratum lucidum. BRCA1 reduction impaired
long-term potentiation (LTP) induced by high-frequency stimu-
lation of mossy fibres (Fig. 6k,l) but did not affect short-term
plasticity, paired-pulse facilitation (Supplementary Fig. 10c) or
post-tetanic potentiation (Supplementary Fig. 10d). These find-
ings suggest that BRCA1 plays a critical role in learning and
memory by maintaining neuronal morphology, firing properties
and synaptic plasticity to ensure proper functioning of cells and
neural circuits.
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Figure 6 | BRCA1 knockdown reduces neuronal size, increases neuronal excitability and impairs LTP. WTmice received injections of scr or sh1
into both DG at 3 months of age as in Fig. 3. Acute brain slices were prepared 45–65 days later. (a–j) GFP-positive granule cells were targeted for
whole-cell patch-clamp recordings, filled with biocytin and immunostained with streptavidin for analysis of cell morphology. (a) Representative maximum
intensity projection images of cell bodies from streptavidin-labelled granule neurons expressing scr or sh1. Scale bar, 5mm. (b) Quantitation of
cell body sizes. n¼ 14–16 cells per group (1–6 cells per mouse from 4 mice). (c) Representative maximum intensity projection images of traced granule cell
dendritic arbours. (d) Quantitation of dendritic arbour sizes expressed as the average total length of dendrites per neuron. n¼ 10–12 cells per group
(1–4 cells per mouse from 4 mice). (e–j) Whole-cell patch-clamp recordings were used to assess neuronal excitability. Action potential firing was induced
with 1.5-s long current stimulation. n¼ 30–33 cells per group (3–9 cells per mouse from 5 mice). (e) Average membrane resistance of patched
granule cells. (f) Representative action potential firing of neurons expressing scr or sh1 in response to stimulation with 250pA. (g) Instantaneous
frequency (1/interspike interval) as a function of stimulation current. (h) Quantitation of the slope of instantaneous frequency versus current curve.
(i) Average frequency (spikes s 1) as a function of stimulation current. (j) Quantitation of the slope of average frequency versus current curve.
(k,l) Field potential recordings were performed in the CA3 stratum lucidum while stimulating mossy fibres; LTP was induced with 125 pulses at 25Hz. n¼ 12
slices per group (2–3 slices per mouse from 5 mice). (k) fEPSP amplitude over time normalized to the average baseline amplitude ( 10 to 0min).
(l) Quantitation of LTP (average of normalized fEPSP amplitude at 35–40min). *Po0.05, **Po0.01, ***Po0.001 versus scr by t-test. Bars represent
means±s.e.m.
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BRCA1 reduction causes abnormal chromatin remodelling.
Depletion of BRCA1 in the DG of hAPP-J20 mice was associated
with markedly increased dimethylation of Lys9 in histone 3
(me2H3(K9)) (Fig. 1a,b). DSB formation triggers repression of
gene expression by dimethylations of histone 3 (ref. 11). Because
these modifications last until DSB repair is complete11, the
increased levels of me2H3(K9) in hAPP-J20 mice likely
reflect diminished repair of DSBs and prolonged chromatin
remodelling.
To test this hypothesis, we reduced BRCA1 levels in primary
cultures of hippocampal neurons by transduction with sh1, using
scr as a negative control (Fig. 7a–c and Supplementary Fig. 3a–c).
The sh1-induced BRCA1 reduction (Fig. 7a,b) was similar to that
caused by Ab (Fig. 1d) and increased gH2A.X and me2H3(K9)
levels (Fig. 4c). Similar increases in me2H3(K9) were detected in
the DG of sh1-injected WT mice and of sh1- or scr-injected
hAPPlow mice (Fig. 7d,e). Total histone 3 levels in the DG were
similar across genotypes and treatments (Supplementary
Fig. 11a,b). Thus, BRCA1 reduction can elicit histone
modifications known to cause gene repression26, and this
effect is exacerbated in the context of pathologically elevated
levels of Ab.
To further explore the relationship between me2H3(K9)
formation and DSBs, we measured me2H3(K9) and gH2A.X
immunoreactivities in dentate granule cells after mice
received 0, 1 or 5Gy of full-body g-irradiation. The number of
gH2A.X foci increased with the dose of radiation, whereas
the number of me2H3(K9) immunoreactive punctae reached
maximal levels at 1Gy and did not increase further at
5Gy (Supplementary Fig. 11c,d). These results confirm in
neurons that me2H3(K9) is related to the formation
of DSBs27.
Discussion
Our study shows that BRCA1 critically contributes to DSB repair
in central neurons and that neuronal reductions in BRCA1 cause
increased persistence of DSBs, abnormal chromatin remodelling,
cellular dysfunction and cognitive deficits. It also identifies
depletions of BRCA1 in brains of patients with MCI or AD, and
provides evidence that these depletions are caused by the
pathological accumulation of Ab, which may promote the
proteasomal degradation of BRCA1 through overactivation of
extrasynaptic NMDA receptors.
In our experimental models, we reduced BRCA1 expression
specifically in the DG for several reasons. Although dentate
granule neurons are relatively resistant to cell death in AD, there
is plenty of evidence for their dysfunction in this condition. For
example, functional magnetic resonance imaging studies showed
profound alterations in the DG of patients with MCI or early
AD28–30. Furthermore, patients with AD have several molecular
abnormalities in dentate granule cells that are also found in
hAPP-J20 mice, including depletion of BRCA1 (this study),
reduction of calbindin and increased expression of collagen VI,
metenkephalin and group IV phospholipase A2 (refs 5,7).
Degeneration of the perforant path, the main afferent input to
the DG, is a well-established feature of AD31,32. The DG also
shows the greatest increase in neuronal DSBs in hAPP mice4, and
can readily be transduced with lentiviral vectors6,33. In addition,
several sensitive behavioural assays exist to evaluate its function
and dysfunction21,34.
Interestingly, knockdown of BRCA1 in both DG caused deficits
in spatial learning and memory in WT mice. In exploring the
mechanisms that may underlie these abnormalities, we discovered
that the size of cell bodies and dendritic arbours was reduced in
neurons expressing low levels of BRCA1. Changes in dendritic
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complexity, including length and branching, also occur in AD
patients35, AD-related animal models36 and other
neurodegenerative diseases37,38.
The reductions in the size of cell bodies and dendritic arbours
were associated with an increase in cell excitability, consistent
with results from computational modelling39,40 and experimental
studies40. Furthermore, neuronal BRCA1 reduction impaired
long-term synaptic plasticity, which is involved in hippocampus-
dependent associative spatial learning and memory41,42.
Additional studies are needed to determine whether these
neuronal alterations result from faulty DSB repair or from
reductions in other functions BRCA1 fulfils in neurons.
Notwithstanding this uncertainty, the alterations in synaptic
plasticity and neuronal excitability we observed after BRCA1
reduction may well contribute to the circuit and network
dysfunctions that underlie cognitive deficits and behavioural
alterations in AD and related animal models5,30,43,44.
The fact that select manipulations in the DG caused
behavioural deficits in the MWM may seem at odds with reports
that complete removal or destruction of both DG does not
prevent mice from solving this task45. However, diverse lines of
evidence suggest that solving this task actively engages the
DG46,47. Other molecular manipulations of both DG also altered
performance in this or other tasks requiring the encoding of
spatial contexts6,34. Conceivably, compensatory mechanisms in
the remainder of the brain are engaged more effectively when a
brain region is eliminated than when it is dysfunctional but still
connected to the network. Indeed, individual neurons can affect
global network activity34.
BRCA1 is critical for DNA repair in dividing cells, in which
BRCA1 deficiency leads to cell death9,11. If it had a similar role in
mature neurons, Ab- and sh1-induced BRCA1 reductions might
impair cognitive functions through neuronal apoptosis resulting
from accumulating DNA damage. However, despite having
impaired learning and memory, WT and hAPPlow mice with
reduced BRCA1 levels showed no evidence for neuronal apoptosis
or loss. Interestingly, BRCA1 reduction impaired the repair of
neuronal DSBs elicited by physiological brain activity in
WT mice. It is tempting to speculate that much of the neuronal
DNA damage that accumulates in brains with reduced BRCA1
levels represents these circumscribed activity-induced DSBs4 and
that chronic accumulation of such DSBs could ultimately
contribute to neuronal degeneration, for example, by
dysregulating gene expression24.
BRCA1 knockdown tended to reduce the number of newborn
granule cells in the DG, but this trend was not statistically
significant. In addition, sh1-injected WT mice and scr-injected
hAPPlow mice had the same level of doublecortin-positive
neurons in the DG (Supplementary Fig. 7), but only the former
group had significant deficits in the MWM probe trial and novel
place recognition task (Fig. 4), suggesting a dissociation between
neurogenesis and sh1-induced behavioural deficits. Furthermore,
even profound suppression of neurogenesis appears to cause only
limited cognitive impairments48. It therefore seems most likely
that the effects of BRCA1 knockdown on learning and memory
reflect changes in neuronal structure and function rather than
neuronal loss and impaired neurogenesis.
It is tempting to speculate that BRCA1-dependent alterations
in neuronal structure and function involve chromatin
remodelling and changes in gene expression. Indeed, the
functions and roles of neuronal activity-associated formation
and repair of DSBs may relate to chromatin remodelling,
coordinated transcription or silencing of gene clusters, or
movement of transposable elements24,49,50. By preventing
effective repair of activity-dependent DSBs, neuronal depletion
of BRCA1 may dysregulate these dynamic processes.
In many non-neuronal cell types, DSB formation is associated
with increased dimethylation on lysine 9 (K9) of histone 3
(ref. 27). We found that this association also exists in mature
post-mitotic neurons. In dividing cells, me2H3(K9) formation is
critically involved in BRCA1-dependent repair processes26 and
mediates gene repression51. Although transient me2H3(K9)
formation in neurons is linked to memory acquisition52,
abnormal persistence of this modification in neurons has been
implicated in behavioural and neuropsychiatric disorders. In our
study, BRCA1 reduction increased neuronal me2H3(K9)
levels in vitro and in vivo, possibly because of the increased
persistence and accumulation of neuronal DSBs. However,
me2H3(K9) levels in the DG were higher in scr-injected
hAPPlow mice than scr-injected WT mice, even though these
groups had comparable numbers of neurons with DSBs.
Conceivably, it may take less Ab elevation and BRCA1
reduction to cause dimethylation of lysine 9 on core histone 3
than to promote the accumulation of DSBs. Alternatively, the
detection of me2H3(K9) by western blot analysis may simply be
more sensitive than gH2A.X immunohistochemistry or the comet
assay. It is also worth noting in this context that irradiated WT
mice had many more me2H3(K9) punctae in the DG than
gH2A.X-positive foci. This dissociation could also reflect
differences in the sensitivity of the methods used to detect the
alterations. It may also suggest that, although me2H3(K9) is
clearly related to the formation of DSBs, it also forms part of
additional processes that are engaged by pathologically elevated
Ab levels and g-irradiation.
The finding that BRCA1 critically contributes to DSB repair in
central neurons was unexpected, as BRCA1 is presumed to be
involved primarily in DNA repair by homologous recombination,
which is not known to occur physiologically in non-dividing cells;
in mature neurons, DSBs appear to be repaired by non-
homologous end joining (NHEJ)2. However, to our knowledge,
the role of BRCA1 in NHEJ has been studied only in mitotic cells,
where it is important for the fidelity of the canonical NHEJ repair
pathways11,53–55. BRCA1 also participates in non-classical NHEJ
pathway: microhomology-mediated end joining and alternative
NHEJ. These pathways allow for genomic stability-conserving
repair and require the functions of BRCA1 and 53BP1
(refs 56–58). Additional studies are needed to determine the
exact pathway(s) through which BRCA1 contributes to the repair
of DSBs in mature post-mitotic neurons.
Another intriguing question our study raises is whether
mutations in BRCA1 that increase the risk for certain cancers
by impairing DNA repair in highly proliferating cells9 also change
the function of BRCA1 in the brain. However, unlike the AD-
associated depletion of BRCA1 in ageing brains and the
experimental knockdown strategy used here, BRCA1 mutations
are present from early stages of embryonic development and thus,
might allow for the compensatory implementation or activation
of alternative DNA repair factors and mechanisms, at least in
neurons. Finally, BRCA1 is a complex protein that may have
functions in the nervous system distinct from those it has in DNA
repair and chromatin remodelling. Additional studies are needed
to address these possibilities and explore the therapeutic potential
of enhancing DNA repair in AD and related conditions.
Methods
Human post-mortem tissues. For BRCA1 immunostaining, sections of 4%
paraformaldehyde-fixed post-mortem brain tissues containing hippocampus from
people without cognitive impairments (controls, n¼ 8, 82.1±5.6 years, mean±
s.e.m) and from patients with MCI (n¼ 8, 87.6±1.5 years) or AD (n¼ 8, 82.0±2.6
years) were obtained from the Alzheimer’s Disease Research Center of the University
of California at San Diego. Clinical diagnoses were based on the criteria described by
Albert et al.59 and McKhann et al.60, and neuropathological diagnoses were based on
the criteria described by Hyman et al.61. Cases met the following criteria: controls,
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clinical dementia rating (CDR) 0 and Braak stage 0–I; MCI cases, CDR 0.5 and Braak
stages I–III; and AD cases, CDR Z1 and Braak stages IV–VI.
For BRCA1 western blot analysis, inferior parietal cortex was dissected from
frozen post-mortem brain tissues of non-demented controls (n¼ 9, age 81.1±4.4
years) and patients with mild AD (n¼ 5, age 84.3±2.2 years) or severe AD (n¼ 8,
age 71.7±6.1 years) obtained from the Alzheimer’s Disease Research Centers of
the University of California at San Diego and the New York Brain Bank of
Columbia University, New York. AD was diagnosed and its severity scored by
Braak staging based on the extent of amyloid plaques and neurofibrillary tangles in
formalin-fixed tissue from the opposite hemibrain according to criteria of the
Consortium to Establish a Registry for Alzheimer’s Disease and the National
Institute on Aging. Cases met the criteria described above.
Mice and brain tissues. We studied 4- to 8-month-old heterozygous hAPP
transgenic mice and WT mice from lines J9 (hAPPlow) and J20 (refs 7,16,19) on a
C57BL6/J background. For g-irradiation, we used 4.5- to 5.5-month-old WT mice
from line J20 (ref. 4). For electrophysiological recordings, we used acute
hippocampal slices from 3- to 5-month-old WT mice from line J9. In vivo analyses
were carried out on sex-matched or sex-balanced groups. Littermates were group
housed. For testing in the MWM, mice were single-housed from 5 days before the
start of training until the test was concluded. All mice had ad libitum access to food
(PicoLab Rodent Diet 20, 5053) and water and were exposed to a 12-h light/dark
cycle. For histological and biochemical analyses, mice were anesthetized with
Avertin (tribromoethanol, 250mg kg 1) and perfused transcardially with 0.9%
NaCl. One hemibrain was used fresh for the comet assay or snap frozen and stored
at –80 C for western blot or quantitative PCR with reverse transcription (RT–
qPCR) analysis. For RT–qPCR analysis, mice were perfused with 0.9% NaCl
containing 0.1% diethylpyrocarbonate. The other hemibrain was drop fixed in 4%
paraformaldehyde in PBS and sectioned (30 mm) with a sliding microtome (Leica
SM2000R). All mouse experiments were approved by the Animal Care and Use
Committee of the University of California, San Francisco.
Lentiviral constructs and stereotaxic injections. Six anti-Brca1 shRNAs were
obtained from Sigma-Aldrich (Mission shRNA lentiviral particles, parental vector
on pLKO.1-purobackbone). Their ability to reduce BRCA1 protein levels was
assessed in primary mouse neuronal cultures 1 week after infection. The sequences
of the two most effective shRNAs (sh1 and sh2) were: sh1: 50-CCACAGGTAAATC
AGGAATTT-30 (ref. 15) and sh2: 50-GTGCTTCCACACCCTACTTAC-30 . The
sh1 sequence is in the coding sequence of BRCA1 mRNA, and the sh2 sequence is
in the 30-untranslated region. The sequence of the control, scrambled shRNA was
50-CCACTACCGTTGTTATAGGTG-30 . Each sequence was inserted into the
FUGW plasmid backbone and used to generate lentiviral vectors as described6,62.
Lentiviruses were bilaterally injected stereotaxically into the DG as described6,
using 1.5 106 titre unit (TU) per DG. No specific method of randomization was
used to determine the treatment of each mouse. GFP expression was used as an
indication of viral transduction. Note, however, that the GFP intensity does not
reliably reflect the abundance of shRNA expressed in transduced cells, as the
promoters driving the expression of these transgenes are activated by different
RNA polymerases: GFP expression is RNA polymerase II dependent, whereas
expression of the shRNA is RNA polymerase III dependent.
Behavioural testing. For all behavioural tests and subsequent analyses, experi-
menters were blinded to the genotype and treatment of mice. Mice were assessed in
the following tests in the indicated sequence and as described in the corresponding
references: elevated plus maze6, open field6, MWM6, novel place recognition6 and
exploration of a novel environment4, with the following modifications. In the
MWM, hidden-platform training was extended to 6 days (from 5 days) to allow
WT mice to reach a steady plateau in their performances without overtraining. The
cued-platform training (two trials per day) was done during the 2 days following
the probe trial, which was carried out 24 h after the hidden-platform training.
Exploration of a novel environment was done 3 weeks after the novel place
recognition test. Two cohorts of WT and transgenic mice from line J9 were
assessed in all tests in the sequence indicated above. An additional cohort from this
line underwent all tests except for the elevated plus maze. To compare the effects of
the two shRNAs, an additional cohort from this line underwent all tests except for
the elevated plus maze, which was replaced by open field testing. Two behaviourally
naive cohorts of mice from line J9 were used for biochemical analyses only. Mice
from line J20 were tested only in the novel environment paradigm.
Cell cultures and treatments. Primary cultures of hippocampal neurons were
established as described4,6, using postnatal day 0 pups from pure C57BL6/J or
C57BL6 FVB/NJ F1 WT mice. Neurons were plated on 12-well plates (Corning)
at 0.5 106 cells per well or on 12-mm glass coverslips coated with poly-D lysine
(Millipore) and laminin (Invitrogen) at low density (150,000 cells per coverslip).
Neurons were infected at 7 days in vitro (DIV) with lentiviral vectors: 1 TU per cell
was used for biochemical analyses and 0.75 TU per cell was used for cell imaging by
fluorescence microscopy. Cultures were used for experiments at 14 DIV, 7 days
after infection. Experimenters were blinded to treatments. Recombinant Ab1–42
oligomers were prepared from lyophilized monomers (rPeptide) as described4,6.
NMDA (Sigma-Aldrich; 10 mM final concentration) was applied to neurons for
5min as described4. Some neuronal cultures were treated with the proteasome
inhibitor MG132 (Sigma-Aldrich; final concentration 10 mM) starting 1 h before
and continuing for 4 h during stimulation of extrasynaptic NMDARs as described4
with the following modification. Cultures were not pretreated overnight with
tetrodotoxin (TTX), (2R)-amino-5-phosphonovalerate (APV), 2,3-dihydroxy-6-
nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX), because this
pretreatment requires extensive subsequent rinses of cells to wash off the
antagonists and leaving out the pretreatment led to more reproducible activation of
extrasynaptic NMDARs.
Western blot analysis. Frozen hemibrains from perfused mice were micro-
dissected in ice-cold PBS containing complete protease inhibitors (Roche) and
homogenized in RIPA buffer (10mM Tris-HCl (pH7.5), 50mM NaCl, 30mM
Na4P2O7, 5 mM ZnSO4, 10% glycerol, 0.1% SDS, 1% Triton X-100 and 1mM
dithiothreitol) containing complete protease inhibitors and a cocktail of phos-
phatase inhibitors (Sigma-Aldrich). Cultured cells were washed in PBS and scraped
into RIPA buffer. Lysates were sonicated for 5min at 4 C and spun in a refri-
gerated microcentrifuge at maximal speed for 10min. Protein concentrations were
determined by Bradford assay.
Proteins (20 mg per mouse sample and 100 mg per human sample) were loaded
on 4–12% Bis-Tris gels (Invitrogen), separated by SDS–PAGE, and transferred to
nitrocellulose membranes. After 1 h in blocking solution (5% non-fat milk in Tris-
buffered saline (TBS)), membranes were incubated with primary antibodies in 5%
non-fat milk in TBS/0.1% Tween (or as indicated below) for 3 h at room
temperature for monoclonal anti-a-tubulin and anti-gH2A.X antibodies and for
polyclonal rabbit anti-Me2H3(K9) (Millipore), or overnight at 4 C for the other
antibodies. Primary antibodies were monoclonal mouse, anti-gH2A.X (JBW301,
Millipore; 1:1,000), anti-MRE11 (12D7, Abcam; 1:1,000) and anti-a-tubulin (B5-1-
2, Sigma-Aldrich; 1:50,000); polyclonal rabbit anti-a-actin (Sigma-Aldrich;
1:1,000), anti-BRCA1 (Abcam; 1:2,000), anti-gH2A.X (PhosphoDetect, Millipore;
1:1,000), anti-total core histone H3 (Millipore; 1:1,000), anti-phospho P42/44
MAPK (p–ERK1/2; 1:1,000), and anti-NBS1 and anti-RAD51 (Abcam; 1:1,000).
Blots were washed three times in TBS/0.1% Tween and incubated with secondary
IRD-tagged antibodies (800 IRDye and 680 IRDye) (Li-COR) diluted 1:10,000 in
Odyssey blocking buffer for 1 h at room temperature.
Western blot signals were analysed with an Odyssey Li-COR laser-scanning and
imaging system (Li-COR, v3.0), except for BRCA1, which could not be detected
with the Li-COR system. BRCA1 was detected with secondary horseradish
peroxidase-tagged antibodies (Calbiochem). Bands were visualized with an ECL kit
(Amersham) and quantified with Image J software. The 23-exon BRCA1 gene gives
rise to different protein isoforms through alternative splicing, and additional
products are derived from some of the isoforms by proteolytic cleavage63. To
quantitate BRCA1 levels, we used the 150-kDa band, which corresponds to the full-
length form of the protein. For display in figures, western blots were cropped to
focus attention on signals of interest; larger sections of the same blots are shown in
Supplementary Figs 12–14.
RT–qPCR analysis. Total RNA was isolated from microdissected frozen mouse
brain tissue (DG or parietal cortex) or from wells of 12-well plates containing
primary neurons with the RNeasy Mini kit (Qiagen) and reverse transcribed with
random hexamers and oligo(dT) primers. Levels of BRCA1 and GAPDH mRNA
were determined with SYBR green PCR reagents and an ABI Prism 7900HT
sequence detector according to the manufacturer’s instructions (Applied Biosys-
tems). The primer sequences used were BRCA1 forward: 50-TGCTCATGCCAGC
TCATTAC-30 ; BRCA1 reverse: 50-ACTGCTATGCCAGGCTGTTT-30 ; GAPDH
forward: 50-GGGAAGCCCATCACCATCTT-30 ; and GAPDH reverse: 50-GCCTT
CTCCATGGTGGTGAA-30 .
For quantification, BRCA1/GAPDH ratios were normalized to the average ratio
in WT mice or in scr- or vehicle-treated neuronal cultures. The quality of all
primers and amplification reactions was assessed by analysis of dissociation curves,
standard curve slopes and reactions lacking reverse transcriptase.
Single-cell gel electrophoresis (comet assay). The comet assay was carried out
at neutral pH as described4,17 and according to the manufacturer’s instructions
(Trevigen). At least 150 nuclei per field were counted and scored in 2–3 fields per
mouse. The number of nuclei with comets was counted manually and expressed as
a percentage of the total number of nuclei inspected in any given mouse. Each
comet detected was framed and a cursor was placed on the head of the comet with
the selection tool of the Cometscore software (Autocomet). The software
automatically determined the tail length using a built-in algorithm for comet
scoring. For each field, the experimenter calculated the average tail length.
Immunocytochemistry. Primary neurons were grown on coverslips for 14 DIV,
rinsed with PBS, fixed in 100% methanol for 10min and rinsed in TBS. Coverslips
were incubated in blocking solution (5% normal goat serum in 0.1% TBS-Tween)
for 1 h at room temperature and then overnight at 4 C with rabbit anti-BRCA1
(ABCam), mouse anti-MAP2 (MAB3418, Millipore) and chicken anti-GFP (GFP-
1010, Aves Labs) antibodies diluted 1:500 in blocking solution. After rinses with
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0.1% TBS-Tween, cells were incubated for 1 h at room temperature with goat anti-
mouse Alexa 647-, anti-chicken Alexa 488- and anti-rabbit Alexa 594-conjugated
secondary antibodies (1:300, Invitrogen) diluted in 4% normal goat serum in TBS.
Human brain sections were immunostained after antigen retrieval in citrate
buffer (pH 6) at 100–115 C for 15min and peroxidase inhibition to enhance
nuclear staining. Nonspecific binding was blocked by incubation for 2 h in blocking
solution (5% normal goat serum in 0.5% TBS-Triton X-100). Sections were
incubated overnight at 4 C with rabbit anti-BRCA1 (Abcam; 1:500 in blocking
buffer). Biotinylated anti-rabbit secondary antibody (Jackson ImmunoResearch)
was diluted similarly and applied to the sections for 1 h at room temperature.
Antibody labelling was visualized with the Avidin–biotin complex kit (Vector
Laboratories) and 3,30-diaminobenzidine tetrahydrochloride (Vector Laboratories).
Immunostaining of mouse brain sections was performed essentially as
described62. However, PBS was replaced with TBS and steps were added for antigen
retrieval and peroxidase inhibition to enhance nuclear staining. Blocking solution
was the same as for neuronal cultures except for doublecortin staining, for which
the blocking solution was 5% normal donkey serum in 0.25% PBS-Triton X-100.
Sections were incubated overnight at 4 C with primary antibodies, including
monoclonal mouse anti-GFP (MAB3580 Millipore), anti-gH2A.X (JBW301,
Millipore), anti-MAP2 (MAB3418 Millipore) and anti-NeuN (MAB377, Millipore);
polyclonal rabbit anti-53BP1 (Novus Biological), anti-BRCA1 (Abcam) and anti-
dimethylated histone H3 (Lys9) (Cell Signaling Technology); and polyclonal goat
anti-doublecortin (Santa Cruz Biotechnology). Primary antibodies were diluted
1:500 (or 1:1,000 for anti-doublecortin) in blocking solution. Secondary antibodies
for detection of GFP, gH2A.X, MAP2, NeuN, 53BP1, Me2H3(K9) and BRCA1
were goat anti-mouse Alexa 488 or anti-rabbit Alexa 594 (Invitrogen). Biotinylated
anti-goat antibodies (Vector Laboratories) were used for doublecortin.
Diaminobenzidine (Vector Laboratories DAB kit) was used as a chromogen. After
extensive rinses, coverslips or sections were mounted with Vectashield mounting
medium with 4,6-diamidino-2-phenylindole (DAPI; Vector Laboratories).
Digitized images of BRCA1 signals were obtained with an all-in-one fluorescence
microscopy system (BZ-9000, Keyence) with built-in camera and analysis software
(BZII viewer and analyser). Images were acquired with identical exposure settings
for BRCA1 signals across all samples in any given experiment. Nuclear and
cytoplasmic levels of BRCA1 were quantified, respectively, with the round and
freehand selection shape and measurement tools from Image J. The 8-bit image of
the red channel, which corresponded to BRCA1 staining, was used to measure
BRCA1 levels; the composite image formed from DAPI and GFP or DAPI and
MAP2 signals was used to determine whether the optical density (OD) of BRCA1
was measured in a GFP-positive or GFP-negative neuron in the DG or in cell
culture. In areas without nuclei in the molecular layer of the DG, background OD
was measured with the shape tool described above and subtracted from all BRCA1
OD signals to calculate BRCA1 immunoreactivities in brain sections. In a coverslip
stained in the absence of primary antibody, background OD was measured with the
shape tools described above, extrapolated to the corresponding areas used for
BRCA1 nuclear and cytoplasmic measurements, and subtracted from all BRCA1
OD signals to obtain BRCA1 immunoreactivities in cell cultures.
For quantification of human BRCA1 signals, digitized images of BRCA1 signals
were obtained with a digital brightfield Olympus BX41 microscope with a DP11
digital camera system. Counterstaining with haematoxylin was used to differentiate
between nucleus and cytoplasm. Nuclear and cytoplasmic regions of neurons on a
threshold-adjusted image were manually annotated with the selection shape and
measurement tools from Image J. BRCA1-positive punctae in each region were
counted semiautomatically with a macro available in Image J. Background signals
were measured on sections stained in the absence of primary antibody and used to
determine the image threshold.
Super resolution z-stacks of images of 53BP1 foci (6.219 mm, 1,800 1,800
pixels), gH2A.X foci and Me2H3(K9) punctae (6.102 mm, 1,240 1,240 pixels), and
MAP2/GFP co-localization (16.462 mm, 1,552 1,552 pixels) were obtained with a
Zeiss LSM880 with an Airyscan detector confocal microscope, a  63 objective,
and, for acquisition of 53BP1 or gH2A.X/Me2H3(K9) nuclear signals, an additional
 2.5 zoom. Images were acquired and processed with Zen 2 software. Z-stacks of
confocal images were processed with Airyscan, and final images were obtained by
orthogonal projection.
53BP1, gH2A.X and doublecortin staining in the DG from coronal sections of
mice was quantified essentially as described4. Counts of 53BP1- or gH2A.X-
positive neurons were averaged from two sections per mouse unless stated
otherwise. Counts of doublecortin-positive neurons were averaged from seven
sections per mouse.
TUNEL staining. TUNEL staining was done with the Apoptag Red In Situ
Apoptosis Detection Kit (EMD Millipore) according to the manufacturer’s
instructions. Briefly, floating brain sections were mounted on Superfrost Plus glass
slides (Fisherbrand). For the TUNEL reaction, sections were incubated in equili-
bration buffer before incubation with the TdT enzyme for 1 h at 37 C in reaction
buffer. The reaction was stopped, and the slides were incubated with anti-digox-
igenin conjugate (rhodamine) for 30min at room temperature, washed three times
in PBS, blocked with 3% donkey serum for 1 h at room temperature and immu-
nostained overnight with anti-GFP or anti-MAP2 antibodies as described above.
Stacks of confocal images were acquired with an MC04 Zeiss LSM510 multiphoton
microscope and Zen software. The appearance of DAPI and GFP/MAP2 labels was
optimized with z-maximum-intensity projection function of ImageJ.
Acute slice electrophysiology. Hippocampal slice preparation. To ensure optimal
health of slices, we prepared acute transverse mouse brain slices (400 mm) with a
modified neuroprotective slicing and recovery method as described64. Mice were
deeply anesthetized with isoflurane and transcardially perfused with 30ml of
chilled oxygenated (95% O2, 5% CO2) slicing artificial cerebrospinal fluid (ACSF;
92mM N-methyl-D-glucamine, 2.5mM KCl, 1.2mM NaH2PO4, 30mM NaHCO3,
20mM HEPES, 25mM glucose, 2mM thiourea, 5mM sodium ascorbate, 3mM
sodium pyruvate, 12mM N-acetyl-L-cysteine, 0.5mM CaCl2 and 10mM MgSO4).
Brains were quickly removed and sliced with a vibrating microtome (HM650V,
Thermo Scientific). Slices were incubated first in slicing ACSF for 10min at 35 C
and then in recovery ACSF (92mM NaCl, 2.5mM KCl, 1.2mM NaH2PO4, 30mM
NaHCO3, 20mM HEPES, 25mM glucose, 2mM thiourea, 5mM sodium ascorbate,
3mM sodium pyruvate, 12mM N-acetyl-L-cysteine, 2mM CaCl2 and 2mM
MgSO4) for 1 h at room temperature. Slices were then transferred to a holding
chamber containing room-temperature oxygenated recording ACSF (126mM
NaCl, 2.5mM KCl, 1.25mM NaH2PO4, 26mM NaHCO3, 12.5mM glucose,
2.5mM CaCl2 and 1.3mMMgSO4) and allowed to equilibrate for at least 1 h before
recording. For recording, slices were placed in a recording chamber mounted on an
Olympus BX51WI microscope equipped with infrared differential interference
contrast optics (900 nm) and perfused with warmed (30–33 C) oxygenated
recording ACSF at a flow rate of 2mlmin 1.
Field potential measurements. Slices were perfused with modified recording
ACSF (125mM NaCl, 2.5mM KCl, 0.8mM NaH2PO4, 26mM NaHCO3, 12.5mM
glucose, 4mM MgCl2 and 4mM CaCl2). A bipolar concentric electrode was placed
in the DG granule cell layer to evoke fEPSPs. fEPSPs were recorded in the stratum
lucidum of the CA3 region with glass micropipettes (3–4MO) filled with recording
ACSF. Data were acquired with a MultiClamp 700B amplifier (Molecular Devices)
and WinLTP software (University of Bristol). The stimulation pulse width was
0.2ms and the stimulation rate was 0.05Hz throughout the experiment unless
otherwise noted. Three responses were averaged for each data point. Mossy fibre
fEPSPs were identified with the following criteria65: (1) negative waveform
restricted to the stratum lucidum; (2) short onset latency (o5ms); (3) fast time
course (o10ms); and (4) selective reduction by the group II metabotropic
glutamate receptor agonist (2 S,20R,30R)-2-(2,3-dicarboxycyclopropyl)glycine
(DCG-IV, 2 mM; Tocris Bioscience). Stimulation strength that elicited 30% of the
maximum response was used to assess paired-pulse facilitation and LTP. Paired-
pulse facilitation was induced with two stimulation pulses 50ms apart, and the
paired-pulse ratio was calculated by dividing the response elicited with the second
pulse by the response elicited with the first pulse. LTP was induced with 125
stimulation pulses at 25Hz. Data were analysed offline with Clampfit software
(Molecular Devices). Slices in which baseline fEPSP responses fluctuated 420%
were excluded from the analysis.
Intrinsic excitability measurements. Intrinsic excitability of DG granule cells was
assessed by recording the frequency of action potentials in response to current
stimulation (FI curve) during synaptic receptor blockade. To block AMPA, NMDA
and GABAA receptors, 20 mM 6,7-dinitroquinoxaline-2,3-dione, 100 mM DL-2-
amino-5-phophonopentanoic acid (DL-APV) and 50 mM picrotoxin were added to
recording ACSF (Tocris Bioscience). Patch pipettes with a tip resistance of 4–6 MO
were filled with a solution consisting 20mM KCl, 100mM K-gluconate, 10mM
HEPES, 4mM Mg-ATP, 0.3mM Na-GTP, 10mM Na-phosphocreatine, 0.2mM
EGTA and 0.2% biocytin (295mOsm, pH 7.35). While the membrane potential of
neurons was held at –75mV, stimulating currents of different amplitudes were
applied in a random sequence to generate an FI curve. To estimate the slopes of
individual FI curves we fit a straight line between the current threshold and 100
(average frequency) or 300 pA (instantaneous frequency) above the current
threshold. Data were analysed offline with a custom analysis programme in IGOR
Pro software (WaveMetrics). Recordings from neurons that had a resting
membrane potential 4 55mV or an access resistance 430MO were excluded
from analysis.
Neuronal reconstruction and morphometry analysis. Before immunostaining,
acute slices containing biocytin-filled dentate granule cells were fixed with 4%
paraformaldehyde for 2 h at room temperature. Sections were maintained in
solutions containing 0.25% Triton X-100 for the entire immunostaining protocol.
Sections were blocked for 1 h at room temperature with 10% goat serum and
incubated overnight at 4 C in anti-GFP (1:500, MAB3580, Millipore) diluted in 3%
goat serum. After PBS washing steps, biocytin-filled neurons were revealed, and the
GFP signal was amplified by co-application of streptavidin-conjugated Alexa-594
(1:500, Invitrogen) and mouse Alexa 488 (1:500, Invitrogen) for 2 h at room
temperature. After final washing steps, slices were mounted in Vectashield
mounting medium with DAPI (Vector Laboratories).
Streptavidin-labelled neurons were visualized using epifluorescence and were
imaged with a spectral confocal microscope (Nikon C1si) and EZ-C1 software.
Whole dendritic trees were imaged with a Plan Fluor  40 objective, 512 512
pixels, and in z-stacks of 0.5-mm steps. Whole cell bodies were imaged with a
Plan  100 objective and appropriate zoom, 512 512 pixels, and in z-stacks of
0.25-mm steps. Neuronal morphology was analysed with Fiji software. To estimate
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the size of cell bodies, z-stacks were flattened into maximum intensity projections,
cell body outlines were traced and the total area of the tracings was quantified.
To estimate the size of dendritic arbours, all dendrites of a given neuron were
traced in three-dimensional with the Simple Neurite Tracer plugin, and their
lengths were summed.
Blind coding and statistical analysis. Investigators who obtained data were
blinded to the disease state of human samples and to the genotype and treatment of
mice and cell cultures. Sample sizes were chosen on the basis of pilot experiments
and our experience with similar experiments. Statistical analyses were performed
with Prism 6 (GraphPad) or R (R Development Core Team). Normal distribution
of the data was verified with D’Agostino and Pearson’s omnibus normality test.
Differences between two means were assessed by unpaired or paired Student’s t-test
or, if the data were not normally distributed, with the Mann–Whitney U-test.
Differences among multiple means were assessed by one-way or two-way analysis
of variance or repeated-measures one-way analysis of variance, followed by Bon-
ferroni’s post hoc tests. Null hypotheses were rejected at the 0.05 level.
To analyse the data obtained in the acquisition phase of the MWM in greater
detail, we estimated learning curves for each genotype-by-treatment pair using a
Bayesian hierarchical model fit by Markov chain Monte Carlo implemented in the
statistical programming language R66. For each pair, the likelihood included a
3-degrees-of-freedom natural cubic spline. For any given trial on a given day, we
also included linearly time-varying effects of three dummy variables, indicating
whether each observation was from the second, third or fourth trial of the day.
These fixed effects were all given flat priors.
To account for the correlation among repeated observations, one random
intercept and three time-spline terms were included for each mouse. For each of
the model’s four variance components (one for the random intercepts and one for
each of the three random spline terms), we used a flat prior on the s.d. scale67. To
account for censoring at 60 s, we used a latent variable approach68 that enabled
Gibbs sampling of all parameters. To determine differences in learning strategies
between the genotypes for a given treatment, we approximated P values by
inverting 95% credible intervals, which represent the 2.5–97.5 percentiles of the
posterior distribution.
To ensure the validity of our model-fitting algorithm, we started three Markov
chain Monte Carlo chains from overdispersed initial values. After 2,500 iterations
of burn-in, we obtained 2,500 additional samples from each chain. Convergence
was achieved, with all chains having Gelman Rubin statistics69 of 1. We combined
the three chains and thinned to obtain 5,000 iterations with which to do inference.
Mixing yielded an average of 3,500 effectively independent samples70 from each
chain.
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